ALX ONCOLOGY HOLDINGS INC (ALXO) research

ALX ONCOLOGY HOLDINGS INC
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$1.70
As of

ALX ONCOLOGY HOLDINGS INC (ALXO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.

As of . Source: SEC EDGAR filings for ALXO. Method and limitations.

SHARE THIS CARD

Share the ALXO intelligence card

A branded snapshot of ALXO: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ALXO intelligence card preview
Post to X
LIVE TERMINAL

See ALXO live in the terminal

Track ALXO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ALXO terminal, free

Active signals for ALXO

FREE, NO ACCOUNT

Every signal on ALXO, as it fires

You are seeing 5 of 6 signals recorded on ALXO since 2026-05-26.

The five above landed across 3 days. The other 1 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ALXO (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 00166B105 · 2026Q2$4.5M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 00166B105 · 2026Q2$3.2M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 00166B105 · 2026Q2$1.2M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ALXO

ALXO against its peers

ALXO's return on equity of -391.4% ranks in the 12th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.

MetricALXOPeer medianPercentilen
Revenue FYn/a25.4Mn/a17
Operating marginn/a-279.5%n/a17
Net marginn/a-240.3%n/a17
Return on equity-391.4%-47.9%1220

Peers (23): NAGE, RNAC, WHWK, CGEN, SLGL, ADAG, YDES, FHTX, IVVD, KROS, NGEN, AVXL, BCYC, ANTX, NKTX, MGNX, PLX, TRDA, LCTX, ELDN, MSLE, ACIU, ALEC. Left out: TNXP (no annual filing), VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ALXO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ALXO signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ALXOand get the insider, 13F, options, and confluence read in one view.

Open the live ALXO terminal, free